Literature DB >> 17639105

Variability of NT-proBNP levels in heart failure: implications for clinical application.

A Mark Richards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17639105      PMCID： PMC1994424          DOI： 10.1136/hrt.2006.110643

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  16 in total

1.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

Authors:  R W Troughton; C M Frampton; T G Yandle; E A Espiner; M G Nicholls; A M Richards
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.

Authors:  Leong L Ng; Ian W Loke; Joan E Davies; Sandeep Geeranavar; Kamlesh Khunti; Margaret A Stone; Derek T Chin; Iain B Squire
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

3.  Clinical relevance of biological variation of B-type natriuretic peptide.

Authors:  Aldo Clerico; Gian Carlo Zucchelli; Alessandro Pilo; Michele Emdin
Journal:  Clin Chem       Date:  2005-05       Impact factor: 8.327

4.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

Authors:  V Cheng; R Kazanagra; A Garcia; L Lenert; P Krishnaswamy; N Gardetto; P Clopton; A Maisel
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

5.  Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study.

Authors:  Raquel Cortés; Miguel Rivera; Antonio Salvador; Vicente Bertomeu; Fernando García de Burgos; Esther Roselló-Lletí; Manuel Portolés; Rafael Payá; Luis Martínez-Dolz; Vicente Climent
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

6.  N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

Authors:  Paulo Bettencourt; Ana Azevedo; Joana Pimenta; Fernando Friões; Susana Ferreira; António Ferreira
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

7.  High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure.

Authors:  Sanne Bruins; M Rebecca Fokkema; Jeroen W P Römer; Mike J L Dejongste; Fey P L van der Dijs; Jody M W van den Ouweland; Frits A J Muskiet
Journal:  Clin Chem       Date:  2004-09-02       Impact factor: 8.327

8.  Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure.

Authors:  Alan H B Wu; Andrew Smith; Stacey Wieczorek; Jeffrey F Mather; Bret Duncan; C Michael White; Carol McGill; Deb Katten; Gary Heller
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

9.  Diagnosis of heart failure using urinary natriuretic peptides.

Authors:  L L Ng; S Geeranavar; S C Jennings; I Loke; R J O'Brien
Journal:  Clin Sci (Lond)       Date:  2004-02       Impact factor: 6.124

Review 10.  Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure.

Authors:  Alan H B Wu; Andrew Smith
Journal:  Eur J Heart Fail       Date:  2004-03-15       Impact factor: 15.534
View more
  4 in total

1.  CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study.

Authors:  Raffaele Altara; Marco Manca; Marleen H Hessel; Yumei Gu; Laura C van Vark; K Martijn Akkerhuis; Jan A Staessen; Harry A J Struijker-Boudier; George W Booz; W Matthijs Blankesteijn
Journal:  J Cardiovasc Transl Res       Date:  2016-06-06       Impact factor: 4.132

2.  Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension.

Authors:  Ken Monahan; Theresa A Scott; Yan Ru Su; Carrie G Lenneman; David X Zhao; Ivan M Robbins; Anna R Hemnes
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

Review 3.  Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.

Authors:  Pablo Garcia-Pavia; Frank Bengel; Dulce Brito; Thibaud Damy; Franz Duca; Sharmila Dorbala; Jose Nativi-Nicolau; Laura Obici; Claudio Rapezzi; Yoshiki Sekijima; Perry M Elliott
Journal:  Eur J Heart Fail       Date:  2021-05-24       Impact factor: 17.349

4.  Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations.

Authors:  Trevor Simard; Richard Jung; Alisha Labinaz; Mohammad Ali Faraz; F Daniel Ramirez; Pietro Di Santo; Dylan Perry-Nguyen; Ian Pitcher; Pouya Motazedian; Chantal Gaudet; Rebecca Rochman; Jeffrey Marbach; Paul Boland; Kiran Sarathy; Saleh Alghofaili; Juan J Russo; Etienne Couture; Steven Promislow; Rob S Beanlands; Benjamin Hibbert
Journal:  J Am Heart Assoc       Date:  2019-08-05       Impact factor: 5.501
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.